Table 3.
Geometric mean titre and geometric mean ratio of humoral responses at day 14 after the third dose vaccination.
| ChAdTS-S (n=48) | RQ3013 (n=46) | ZR202-CoV (n=47) | CoronaVac (n=46) | Placebo (n=46) | |
|---|---|---|---|---|---|
| Neutralising antibodies against the wild-type of live SARS-CoV-2 | |||||
| GMT | 289.6 | 950.1 | 635.2 | 75.4 | 5.4 |
| (232.2-361.2) | (785.4-1149.3) | (524.0-770.1) | (61.4-92.5) | (4.5-6.4) | |
| GMR1 | 56.8 | 190.9 | 120.8 | 15.1 | Ref |
| (43.6-74.1) | (145.8-249.9) | (92.6-157.6) | (11.5-19.8) | - | |
| GMR2 | 3.8 | 12.6 | 8.0 | Ref | - |
| (2.9-4.9) | (9.6-16.5) | (6.1-10.4) | - | - | |
| p1 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | Ref |
| p2 | <0.0001 | <0.0001 | <0.0001 | Ref | - |
| Neutralising antibodies against the delta variant of live SARS-CoV-2 | |||||
| GMT | 226.0 | 796.9 | 491.9 | 54.3 | 4.3 |
| (187.2-273.0) | (667.7-951.1) | (411.6-587.9) | (42.4-69.4) | (3.9-4.8) | |
| GMR1 | 52.8 | 185.0 | 113.9 | 12.6 | Ref |
| (41.0-68.1) | (143.2-239.1) | (88.3-147.0) | (9.7-16.3) | - | |
| GMR2 | 4.2 | 14.7 | 9.1 | Ref | - |
| (3.3-5.4) | (11.4-19.1) | (7.0-11.7) | - | - | |
| p1 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | Ref |
| p2 | <0.0001 | <0.0001 | <0.0001 | Ref | - |
| Neutralising antibodies against the omicron variant (BA.1.1) of live SARS-CoV-2 | |||||
| GMT | 40.5 | 247.0 | 103.8 | 8.1 | 4.0 |
| (31.2-52.5) | (194.1-314.3) | (84.0-128.3) | (6.1-10.7) | (4.0-4.0) | |
| GMR1 | 10.3 | 62.4 | 26.0 | 2.0 | Ref |
| (7.6-14.0) | (45.8-85.1) | (19.1-35.4) | (1.5-2.7) | - | |
| GMR2 | 5.2 | 31.3 | 13.0 | Ref | - |
| (3.8-7.0) | (22.9-42.7) | (9.6-17.7) | - | - | |
| p1 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | Ref |
| p2 | <0.0001 | <0.0001 | <0.0001 | Ref | - |
| Neutralisation antibodies measured by competitive inhibition method | |||||
| GMT | 19512.9 | 90384.3 | 51995.0 | 4588.2 | 165.2 |
| (15498.4-24567.1) | (71218.5-114707.9) | (41583.4-65013.4) | (3558.8-5915.5) | (127.2-214.7) | |
| GMR1 | 138.4 | 640.6 | 345.7 | 33.2 | Ref |
| (101.8-188.2) | (469.7-873.8) | (254.5-469.6) | (24.3-45.3) | - | |
| GMR2 | 4.2 | 19.3 | 10.4 | Ref | - |
| (3.1-5.7) | (14.2-26.3) | (7.7-14.2) | - | - | |
| p1 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | Ref |
| p2 | <0.0001 | <0.0001 | <0.0001 | Ref | - |
Note: Geometric mean ratio (GMR) was calculated using linear regression model by adjusting for the baseline neutralising antibody levels at day 0 before the booster dose vaccination, the first and second dose interval, and the second and third dose interval. GMR1 and p1 were calculated by comparing to placebo group, while GMR2 and p2 were calculated by comparing to the CoronaVac group.